From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Private Eye on Novacyt - this is damning

By Tom Winnifrith | Sunday 30 January 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I have warned you time and time again that Novacyt (NCYT) was a ramp with the sole purpose of allowing now departed CEO Graham Mullis to trouser an enormous cash bonus based on the share price on just one day. In the end Mullis trousered £8.5 million but, last week, Private Eye served up a great article showing how the company has a cultrure of lying and fabrication and, had investors known the truth about tests that did not work or which were contaminated, Mullis would be far less well off than he is today. This is a scandal and the ramifications could be very serious. Potentially a claim by the DHSC could wipe out most of this  company’s balance sheet (cash of £100million) with ongoing cash burn now that sales of its covid tests are evaporating, taking out the rest. This remains a bargepole stock/short.  The article is below. 

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 13:08:51